Millennium Pharmaceuticals Limited

Portola Pharmaceuticals, Inc.

Stanley J Hollenbach

Uma Sinha

Genmin Lu

Athiwat Hutchaleelaha

Patrick Andre

Keith Abe

The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor Xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

Unit dose formulation of antidotes for factor Xa inhibitors and methods of using the same

The present invention is directed to methods of using combination therapies containing [2-({4-[(dimethylamino)iminomethyl]phenyl}carbonylamino)-5-methoxyphenyl]-N-(5-chloro(2-pyridyl))carboxamide for the treatment of thrombotic disease(s) and pharmaceutical compositions thereof.

Combination anticoagulant therapy with a compound that acts as a factor Xa inhibitor

Unit doses of factor Xa inhibitor compounds and methods of using these compounds for inhibiting blood coagulation in a human patient are taught herein. The unit dose of the factor Xa inhibitor compounds disclosed herein required to inhibit coagulation in a primate is lower than the unit dose required to obtain similar levels of coagulation inhibition in other animal models, such as rodents. Also taught are in vitro assays useful in predicting in vivo antithrombotic activity in humans.

Growing community of inventors

South San Francisco, CA, United States of America

Stanley J Hollenbach